Skip to main content

Table 3 Adjunct antithrombotic therapy

From: Design and rationale of the AngioSeal versus the Radial approach In acute coronary SyndromE (ARISE) trial: a randomized comparison of a vascular closure device versus the radial approach to prevent vascular access site complications in non-ST-segment elevation acute coronary syndrome patients

Site Emergency unit Catheter lab Coronary unit and/or ward Home use duration
Drug     
Aspirin 300 mg orally No 100 mg per day orally 100 mg per day orally, indefinitely
Clopidogrel 600 mg orally No 75 mg per day orally 75 mg per day orally, 12 months
Prasugrel 60 mg orally No 10 mg per day orally 10 mg per day orally, 12 months
Ticagrelor 180 mg orally No 90 mg twice daily orally 90 mg twice daily orally, 12 months
Enoxaparin 1 mg per kg SC 0.3 mg per kg IV if the last dose is 8 to 12 hours 0.5 to 0.75 mg per kg IV if the last dose is >12 hours 1 mg per kg SC twice daily No
Fondaparinux 2.5 mg SC 85 UI per kg IV UFH or 60 UI per kg IV UFH if GPI is scheduled 2.5 mg/SC/day No
Abciximab No Intravenous loading dose of 0.25 mg per kg 0.125 mcg per kg per min for 12 hours, IV, without using HNF No
Tirofiban No Intravenous loading dose of 25 mcg per kg 0.15 mcg per kg per min for 12 to 18 hours, IV, without using HNF No
  1. GPI, IIb-IIIa glycoprotein receptor inhibitor; UFH; unfractionated heparin, IV, intravenous; SC subcutaneous.